Maple Syrup Urine Disease Type II via the DBT Gene

Summary and Pricing

Test Method

Exome Sequencing with CNV Detection
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
9395 DBT 81406 81406,81405 $890 Order Options and Pricing
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
9395DBT81406 81405(x1), 81406(x1) $890 Order Options and Pricing

Pricing Comments

Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if full gene Sanger sequencing is desired for STAT turnaround time, insurance, or other reasons, please see link below for Test Code, pricing, and turnaround time information. If the Sanger option is selected, CNV detection may be ordered through Test #600.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing backbone).

Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing backbone).

The Sanger Sequencing method for this test is NY State approved.

For Sanger Sequencing click here.

Turnaround Time

18 days on average for standard orders or 13 days on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.

EMAIL CONTACTS

Genetic Counselors

Geneticist

Clinical Features and Genetics

Clinical Features

Maple syrup urine disease (MSUD; OMIM 248600) is a heterogeneous organic aciduria disorder caused by the impairment of the branched-chain α-keto acid dehydrogenase complex (BCKD). BCKD is a mitochondrial complex, encoded by four nuclear genes (BCKDHA, BCKDHB, DBT, and DLD), which is involved in the metabolism of the branched-chain amino acids leucine, isoleucine, and valine (Morton et al. Pediatrics 109:999-1008, 2002; Nellis et al. Molec Genet Metab 80:189-195, 2003; Chuang et al. J Biol Chem 279:17792-17800, 2004). Defective BCKD complex activity leads to the accumulation of the branch-chain amino acids to toxic levels (Chuang et al. 2004). MSUD, in untreated neonates, is characterized by mental and physical retardation, maple syrup odor in cerumen and urine, poor feeding, ketonuria, irritability, lethargy, intermittent apnea, opisthotonus, stereotyped movements such as “fencing” and “bicycling,” coma, and respiratory failure. Biochemically, MSUD is characterized by elevated plasma concentrations of branched-chain amino acids (leucine, isoleucine, and valine) and allo-isoleucine, as well as a generalized disturbance of plasma amino acid concentration ratios (Schadewaldt et al. Clin Chem 45:1734-1740, 1999; Morton et al. 2002; Nellis et al. 2003; Chuang et al. 2004).

Genetics

MSUD is an autosomal recessive genetically heterogeneous disorder caused by variants in one of the four BCKD complex encoded genes (BCKDHA, BCKDHB, DBT, and DLD). MSUD Type II is caused by variants in the DBT gene, which encodes the dihydrolipoyl transacylase; the E2 component of the BCKD complex (Hummel et al. J Biol Chem 263:6165- 6168, 1988; Danner et al. J. Biol. Chem. 264: 7742-7746, 1989). A mix of missense, nonsense, splicing, regulatory, small deletion variants as well as gross deletion variants within the DBT gene have been reported (Herring et al. Am J Hum Genet 48:342-350, 1991; Fisher et al. Am J Hum Genet 52:414-424, 1993; Tsuruta et al. J Hum Genet 43:91-100, 1998; Henneke et al. Hum Mutat 22:417-422, 2003; Chuang et al. 2004; Rodriguez et al. Hum Mutat 27:715-727, 2006; Brodtkorb et al. Mol Genet Metab 100:324-332, 2010).

Clinical Sensitivity - Sequencing with CNV PGxome

It has been reported that variants in the DBT gene are responsible for approximately 19% of the MSUD cases, while variants in the BCKDHA and the BCKDHB genes are responsible for approximately 33% and 38% of MSUD cases, respectively (Nellis and Danner. Am J Hum Genet 68:232-237, 2001).

Testing Strategy

This test provides full coverage of all coding exons of the DBT gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).

Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).

Indications for Test

Candidates for this test are patients with symptoms consistent with MSUD and family members of patients who have known DBT variants. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in DBT.

Gene

Official Gene Symbol OMIM ID
DBT 248610
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Disease

Name Inheritance OMIM ID
Maple Syrup Urine Disease AR 248600

Related Tests

Name
Maple Syrup Urine Disease Panel
Maple Syrup Urine Disease Type IA via the BCKDHA Gene
Maple Syrup Urine Disease Type IB via the BCKDHB Gene

Citations

  • Brodtkorb, E., et.al. (2010). "Four novel mutations identified in Norwegian patients result in intermittent maple syrup urine disease when combined with the R301C mutation." Mol Genet Metab 100(4): 324-32. PubMed ID: 20570198
  • Chuang, J. L., et.al. (2004). "Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients: a proposed mechanism for the thiamin-responsive phenotype." J Biol Chem 279(17): 17792-800. PubMed ID: 14742428
  • Danner, D. J., et.al. (1989). "Construction and nucleotide sequence of a cDNA encoding the full-length preprotein for human branched chain acyltransferase." J Biol Chem 264(13): 7742-6. PubMed ID: 2708389
  • Fisher, C. W., et.al. (1993). "Occurrence of a 2-bp (AT) deletion allele and a nonsense (G-to-T) mutant allele at the E2 (DBT) locus of six patients with maple syrup urine disease: multiple-exon skipping as a secondary effect of the mutations." Am J Hum Genet 52(2): 414-24. PubMed ID: 8430702
  • Henneke, M., et.al. (2003). "Identification of twelve novel mutations in patients with classic and variant forms of maple syrup urine disease." Hum Mutat 22(5): 417 - 422. PubMed ID: 14517957
  • Herring, W. J., et.al. (1991). "Molecular genetic basis of maple syrup urine disease in a family with two defective alleles for branched chain acyltransferase and localization of the gene to human chromosome 1." Am J Hum Genet 48(2): 342-50. PubMed ID: 1990841
  • Hummel, K. B., et.al. (1988). "Nucleotide sequence of a cDNA for branched chain acyltransferase with analysis of the deduced protein structure." J Biol Chem 263(13): 6165-8. PubMed ID: 3245861
  • Morton, D. H., et.al. (2002). "Diagnosis and treatment of maple syrup disease: a study of 36 patients." Pediatrics 109(6): 999-1008. PubMed ID: 12042535
  • Nellis, M. M., Danner, D. J. (2001). "Gene preference in maple syrup urine disease." Am J Hum Genet 68(1): 232-7. PubMed ID: 11112664
  • Nellis, M. M., et.al. (2003). "Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression." Mol Genet Metab 80(1-2): 189-95. PubMed ID: 14567968
  • Rodriguez-Pombo, P., et.al. (2006). "Mutational spectrum of maple syrup urine disease in Spain." Hum Mutat 27(7): 715-727. PubMed ID: 16786533
  • Schadewaldt, P., et.al. (1999). "Significance of L-alloisoleucine in plasma for diagnosis of maple syrup urine disease." Clin Chem 45(10): 1734-40. PubMed ID: 10508118
  • Tsuruta, M., et.al. (1998). "Molecular basis of intermittent maple syrup urine disease: novel mutations in the E2 gene of the branched-chain alpha-keto acid dehydrogenase complex." J Hum Genet 43(2): 91-100. PubMed ID: 9621512

Ordering/Specimens

Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page


Specimen Types

Specimen Requirements and Shipping Details

PGxome (Exome) Sequencing Panel

PGnome (Genome) Sequencing Panel

loading Loading... ×

ORDER OPTIONS

View Ordering Instructions

1) Select Test Method (Backbone)


1) Select Test Type


2) Select Additional Test Options

STAT and Prenatal Test Options are not available with Patient Plus.

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: $
×
Copy Text to Clipboard
×